ARX788 meets PFS end point in HER2+ metastatic breast cancer

Data from an interim analysis of the randomized phase 3 ACE-Breast-02 trial show that anti-HER2 antibody drug conjugate ARX788 significantly improved progression-free survival in patients with HER2-positive metastatic or locally advanced breast cancer, compared with an active control. In other studies, ARX788 has demonstrated activity and acceptable tolerability.